Oncotelic Therapeutics, Inc. - $OTLC STOCK NEWS

Oncotelic Therapeutics announced that Chief Clinical Officer Dr. Anthony Maida will present at the ASCO 2024 meeting. Key topics include:

1. A meta-analysis (abstract e16318) comparing serious adverse events, overall survival, and progression-free survival in pancreatic adenocarcinoma patients treated with modified FOLFIRINOX versus the standard regimen.

2. A study (abstract e14564) on the prognostic impact of TGFB2 mRNA levels, interferon-gamma receptor activation of IRF5, and CD276/B7-H3 expression in low-grade gliomas.

The presentation aims to provide insights into treatment outcomes and prognostic factors in these cancers.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) will be presenting at the Biopharma Nexus Conference in San Diego 2024. Dr. Andy Hu, Nanomedicine Manager, will discuss Nanomedicines: Past, Present, Future. Dr. Hu is an expert in nanomedicine and biotherapeutics, aiming to enhance human health through innovative technologies.

Oncotelic Therapeutics, Inc. has agreed to sell its necroptosis cancer therapy assets to Mosaic ImmunoEngineering, Inc. The deal includes rights to Oncotelic's clinical-stage necroptosis cancer therapies and AI technologies for identifying immunotherapy combinations. Mosaic will issue $15 million in CPMV shares to Oncotelic, with potential for an additional $15 million in shares. The Mosaic team, experienced in bringing oncology products to market, will lead the development. Both companies will collaborate for a smooth transition of technologies. The agreement is subject to negotiation of definitive agreements and customary conditions.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) announces a groundbreaking peer-reviewed publication on the therapeutic targeting of negative prognostic markers in low-grade gliomas. The study reveals the crosstalk between TGF-β and IFN signaling pathways, offering new strategies for treating gliomas and Systemic Lupus Erythematosus (SLE). The research identifies IRF5 as a common target for both diseases, potentially revolutionizing cancer treatment by modulating the immune response. Detailed analysis shows that low mRNA levels of TGFB2 and IFNGR2 result in improved survival for LGG patients, highlighting potential therapeutic targets for high-risk patients.

Oncotelic Therapeutics, Inc (OTLC) announces the initiation of the STOP-PC clinical trial for advanced pancreatic cancer. The trial focuses on OT-101, a novel RNA therapeutic targeting TGF-β2 to enhance immune response and inhibit tumor growth. Notably, OT-101 has shown promising single-agent activity with dose-dependent survival benefits. The Phase 2/3 trial will evaluate OT-101 in combination with mFOLFIRINOX compared to mFOLFIRINOX alone as second-line therapy for progressing cancer.

Oncotelic Therapeutics, Inc announced the publication of a study on the impact of TGFB2 and IFNGR2 mRNA levels in pediatric DMG patients. The study reveals that elevated TGFB2 levels worsen mortality in DMG patients and highlights the potential of IFNGR2 in enhancing immune surveillance for cancer immunotherapy. The findings suggest that targeting TGFB2 and IFNGR2 could lead to improved overall survival outcomes for pbDMG patients.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) unveils a state-of-the-art GMP Manufacturing Plant in a joint venture with Sapu Biosciences LLC, marking a significant stride in biopharmaceutical innovation and a pivotal expansion in the company's clinical pipeline.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced its CEO, Dr. Vuong Trieu, will be a featured speaker at the Ibero-American Chatbot and Conversational AI Summit. He will discuss the Company’s proprietary chatbots, part of the Orion AI Technology suite, at the November 29th and 30th, 2023 summit. The chatbots aim to overcome traditional AI communication challenges and have multilingual capabilities, advancing global participation in biotechnological innovation.

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced financial results for Q3 2023, showing unchanged R&D costs, significantly lower G&A costs, and reduced net loss and operating expenses. The company is benefitting from a joint venture with Dragon Overseas Limited, which has absorbed most R&D and G&A expenditures related to OT-101, allowing the company to continue development efforts at no cash cost. Plans for an initial public offering of the joint venture in Hong Kong or another exchange are in progress, and the company aims to accelerate clinical programs in multiple indications.